Combination treatment of hepatic encephalopathy due to thioacetamide-induced fulminant hepatic failure in the rat with benzodiazepine and opioid receptor antagonists

Journal of Hepatology

Volumn 31, Issue 5, 1999, Pages 880-886

  Çelik, Turgay ^a   Uzbay, I Tayfun ^a   Çinar, Kubilay ^b   Bozkaya, Hakan ^b   Uzunalimoǧlu, Özden ^b   Yurdaydm, Cihan ^c  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b TRABZON   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

Author keywords

Hepatic encephalopathy; Naloxone; Ro 15 3505; Thioacetamide

Indexed keywords

BENZODIAZEPINE RECEPTOR BLOCKING AGENT; NALOXONE; OPIATE ANTAGONIST; SARMAZENIL; THIOACETAMIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CHOICE; HEPATIC ENCEPHALOPATHY; LIVER FAILURE; LOCOMOTION; MALE; NEUROLOGIC EXAMINATION; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL;

EID: 0032694443     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80290-6     Document Type: Article

References (32)

1. Butterworth RF. Hepatic encephalopathy: disorder of multiple neurotransmitter systems. Record C, Al-Mardini H. Advances in Hepatic Encephalopathy and Metabolism in Liver Disease. 1997;167-175 Ipswich Book Co. Ltd. Medical Faculty, Newcastle upon Tyne.
2. Basile AS, Jones EA. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology. 25:1997;1303-1305.
3. Yurdaydin C, Li Y, Ha J-H, Rothman R, Basile AS. Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid receptor antagonists. J Pharmacol Exp Ther. 273:1995;185-192.
4. Yurdaydin C, Hörtnagl H, Steindl P, Zimmermann C, Pifl C, Singer EA, et al. Increased serotoninergic and noradrenergic activity in hepatic encephalopathy in rats with thioacetamide-induced acute liver failure. Hepatology. 11:1990;371-378.
5. Gammal SH, Basile AS, Geller D, Skolnick P, Jones EA. Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands. Hepatology. 11:1990;371-378.
6. Steindl P, Püspök A, Druml W, Ferenci P. Beneficial effect of pharmacological modulation of the GABAA-benzodiazepine receptor on hepatic encephalopathy in the rat: comparison with uremic encephalopathy. Hepatology. 14:1991;963-968.
7. Yurdaydin C, Herneth AM, Püspök A, Steindl P, Singer EA, Ferenci P. Modulation of hepatic encephalopathy in rats with thioacetamide-induced acute liver failure by serotonin antagonists. Eur J Gastroenterol Hepatol. 8:1996;667-671.
8. Grimm G, Ferenci P, Katzenschlager R, Madl C, Schneeweiss B, Laggner AN, et al. Improvement of hepatic encephalopathy treated with flumazenil. Lancet. 2:1988;1392-1394.
9. Bansky G, Meier PJ, Riederer E, Walser H, Ziegler WH, Schmid M. Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterolo. 97:1989;744-750.
10. Pomier-Layrargues G, Giguère JF, Lavoie J, Perney P, Gagnon S, D'Amour M, et al. Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. Hepatology. 19:1994;32-37.
11. Millan MJ, Herz A. The endocrinology of the opioids. Intern Rev Neurobiol. 26:1985;1-83.
12. Cooper JR, Bloom FE, Roth RH. Neuroactive peptides. The Biochemical Basis of Neuropharmacology, 6th ed. 1991;381-427 Oxford University Press, New York, Oxford.
13. Herneth AM, Püspök A, Steindl P, Ferenci P. Effect of benzodiazepine and serotonin antagonists on experimental hepatic encephalopathy. J Hepatol. 18:1993;S58.
14. Haefely W, Kyburz E, Gerecke M, Möhler H. Recent advances in the molecular pharmacology of benzodiazepine receptors and in the structure-activity relationships of their agonists and antagonists. Adv Drug Res. 14:1985;165-322.
15. Zimmermann C, Ferenci P, Pifl C, Yurdaydin C, Ebner J, Lassmann H, et al. Hepatic encephalopathy in thioacetamideinduced acute liver failure in rats. Characterisation of an improved model and study of aminoacid-ergic neurotransmission. Hepatology. 9:1989;594-601.
16. Bures J, Buresova O, Huston JP. Innate and motivate behavior. Techniques and Basic Experiments for the Study of Brain and Behavior. 1976;37-45 Elsevier North Holland, New York.
17. Yurdaydin C, Gu Z-Q, Nowak G, Fromm C, Holt AG, Basile AS. Benzodiazepine receptor ligands are elevated in an animal model of hepatic encephalopathy: relationship between brain concentration and severity of encephalopathy. J Pharmacol Exp Ther. 265:1993;565-571.
18. Bosman DK, van den Buijs CACG, de Haan JG, Maas MAW, Chamuleau RAFM. The effects of benzodiazepine receptor antagonists and partial inverse agonists on acute hepatic encephalopathy in the rat. Gastroenterology. 101:1991;772-781.
19. Gardner CR. Pharmacological profiles in vivo of benzodiazepine receptor ligands. Drug Devel Res. 12:1988;1-28.
20. Jones EA. Benzodiazepine receptor ligands and hepatic encephalopathy: further unfolding of the GABA story. Hepatology. 14:1991;1286-1290.
21. Jaffe JH, Martin WR. Opioid analgesics and antagonists. Gilman AG, Rall TW, Nies AS, Taylor P. The Pharmacological Basis of Therapeutics, Vol. 1, 8th ed. 1991;485-521 Pergamon, New York.
22. Holaday JW. Endogenous Opioids and Their Receptors. Kalamazoo MI: The Upjohn Company. 1985.
23. Chang KJ, Cuatrecasas P. Heterogeneity and properties of opiate receptors. Fed Proc. 40:1981;2729-2734.
24. Leander DJ, Hart JC, Lochner MA, Hynes MD, Zimmermannn DM. Novel phenylpiperidine opioid antagonists and partial agonists: effects on fluid consumption. Eur J Pharmacol. 81:1982;185-192.
25. Yurdaydm C, Karavelioǧlu D, Onaran O, Çelik T, Yaşa MH, Uzunalimoǧlu Ö. Opioid receptor ligands in human hepatic encephalopathy. J Hepatol. 29:1998;796-801.
26. Püspök A, Herneth A, Steindl P, Ferenci P. Hepatic encephalopathy in rats with thioacetamide-induced acute liver failure is not mediated by endogenous benzodiazepines. Gastroenterology. 105:1993;851-857.
27. Aronin N, Difiglia M, Graveland G, Schwartz WJ, Wu J-Y. Localization of immunoreactive enkephalins in GABA synthesizing neurons of the rat neostriatum. Brain Res. 300:1984;376-380.
28. Örtel WM, Riethmüller G, Mugnaini E, Schmechel DE, Weindl A, Gramsch C, et al. Opioid-like immunoreacitivity localized in GABAergic neurons of rat neostriatum and central amygdaloid nucleus. Life Sci. (Suppl 1):1983;73-76.
29. Sivam SP, Hong J-S. GABAergic regulation of enkephalin in rat striatum: alterations in met-enkephalin level, precursor content and preproenkephalin messenger RNA abundance. J Pharmacol Exp Ther. 237:1986;326-331.
30. Mullen KD. Optimal animal models for the study of hepatic encephalopathy and nitrogen metabolism. Capocaccio L, Merli M, Riggo O. Advances in Hepatic Encephalopathy and Metabolic Nitrogen Exchange. 1995;279-292 CRC Press, Boca Raton, Florida.
31. Mullen KD, McCullough AJ. Problems with animal models of chronic liver disease: suggestions for improvement in standardisation. Hepatology. 9:1989;500-503.
32. Mullen KD, Rössle KD, Jones DB, Grun M, Jones EA. Precipitation of overt encephalopathy in the portacaval shunted rat: towards the development of an adequate model of chronic portal systemic encephalopathy. Eur J Gastroenterol Hepatol. 9:1997;293-298.